Trial Profile

Multiple-dose phase I trial to evaluate the tolerability and pharmacokinetics of NGX 426 in volunteers.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Feb 2009

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasolampanel (Primary)
Indications Migraine; Neuropathic pain; Pain
Focus Adverse reactions
Sponsors TorreyPines Therapeutics Inc

Most Recent Events

11 Feb 2009 Results were reported in a media release from TorreyPines Therapeutics.
11 Feb 2009 Status changed from recruiting to completed, as reported in media release from TorreyPines Therapeutics.
10 Oct 2008 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com